We’re excited to announce our new partnership with Kubera N.A. LLC, headquartered in New York. Under this agreement, Kubera will support PolTREG S.A. in securing U.S. financing on terms optimized for our growth.

This collaboration runs in parallel and synergy with our recently signed agreement with Noble Capital Markets Inc.

Over the past few years, PolTREG has been intensively developing its project pipeline. Today, we’re a leading platform for a range of cell‑therapy approaches, including polyclonal TREG, CAR‑TREG, allogeneic TREG, antigen‑specific TREG and TCR‑TREG therapies.

We selected Kubera N.A. LLC as our financial advisor following a thorough analysis and numerous discussions with investment banks and transaction advisors. Their expertise and U.S. network make them the great partner to help us navigate the American financing landscape.